Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Gabr, Amir A ^a   Reed, Mathew ^b   Newman, Donna R ^a   Pohl, Jan ^b   Khosla, Jody ^a   Sannes, Philip L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; PROTEOME;

ANIMAL; ARTICLE; COMPARATIVE STUDY; CYTOSKELETON; DRUG EFFECT; FISCHER 344 RAT; GENE EXPRESSION REGULATION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METHODOLOGY; PROTEOMICS; RAT; REFERENCE VALUE; ULTRASTRUCTURE;

ADMINISTRATION, INHALATION; ANIMALS; ANTICOAGULANTS; CYTOSKELETON; GENE EXPRESSION REGULATION; HEPARIN; LUNG; PROTEOME; PROTEOMICS; RATS; RATS, INBRED F344; REFERENCE VALUES;

EID: 34447099094     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-36     Document Type: Article

References (58)

1. Hanash S. Disease proteomics. Nature 2003, 422:226-232. 10.1038/nature01514, 12634796.
2. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004, 3:179-196. 10.1021/pr0499693, 15113093.
3. Fehniger TE, Sato-Folatre JG, Malmstrom J, Berglund M, Lindberg C, Brange C, Lindberg H, Marko-Varga G. Exploring the context of the lung proteome within the airway mucosa following allergen challenge. J Proteome Res 2004, 3:307-320. 10.1021/pr0499702, 15113108.
4. Li CM, Newman D, Khosla J, Sannes PL. Heparin inhibits DNA synthesis and gene expression in alveolar type II cells. Am J Respir Cell Mol Biol 2002, 27:345-352.
5. Sannes PL, Khosla J, Cheng PW. Sulfation of extracellular matrices modifies responses of alveolar type II cells to fibroblast growth factors. Am J Physiol 1996, 271:L688-697.
6. Sannes PL, Khosla J, Li CM, Pagan I. Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata. Am J Physiol 1998, 275:L701-708.
7. Larsen K, Malmstrom J, Tufvesson E, Marko-Varga G, Westergren-Torsson G. Antiprolilferative heparan sulfate inhibiting hyaluronan and transforming growth factor-b expression in human lung fibroblast cells. Clin Proteomics J 2004, 1:271-284.
8. Malmstrom J, Marchese J, Juhasz P, Pukac L, Karnovsky M, Marko-Varga G, Westergren-Thorsson G. Quantitative proteomic analysis of fibroblast nuclear proteins after stimulation with mitogen activated protein kinase inhibiting heparan sulfate. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 815:333-342. 10.1016/j.jchromb.2004.11.054, 15652821.
9. Sasaki M, Kashima M, Ito T, Watanabe A, Sano M, Kagaya M, Shioya T, Miura M. Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity. Mediators Inflamm 2000, 9:85-91. 1781749, 10958381, 10.1080/096293500411541.
10. Kanabar V, Hirst SJ, O'Connor BJ, Page CP. Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle. Br J Pharmacol 2005, 146:370-377. 10.1038/sj.bjp.0706333, 16025136.
11. Yu L, Quinn DA, Garg HG, Hales CA. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005, 97:937-945. 10.1161/01.RES.0000188211.83193.1a, 16195480.
12. Xu J, Park PW, Kheradmand F, Corry DB. Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol 2005, 174:5758-5765.
13. Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W, 168 V, 11 I, 1358 SP, 1365 OP. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003, 168:1358-1365. 10.1164/rccm.2201082, 14644925.
14. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2:521-528. 10.1038/nrc842, 12094238.
15. Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med 1996, 153:1702-1707.
16. Cripps JG, Crespo FA, Romanovskis P, Spatola AF, Fernandez-Botran R. Modulation of acute inflammation by targeting glycosaminoglycan-cytokine interactions. Int Immunopharmacol 2005, 5:1622-1632. 10.1016/j.intimp.2005.04.010, 16039552.
17. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993, 329:90-95. 10.1056/NEJM199307083290204, 8510708.
18. Stradal TB, Gimona M. Ca(2+)-dependent association of S100A6 (Calcyclin) with the plasma membrane and the nuclear envelope. J Biol Chem 1999, 274:31593-31596. 10.1074/jbc.274.44.31593, 10531365.
19. Koulen P, Ehrlich BE. Reversible block of the calcium release channel/ryanodine receptor by protamine, a heparin antidote. Mol Biol Cell 2000, 11:2213-2219. 14914, 10888663.
20. Amieva MR, Furthmayr H. Subcellular localization of moesin in dynamic filopodia, retraction fibers, and other structures involved in substrate exploration, attachment, and cell-cell contacts. Exp Cell Res 1995, 219:180-196. 10.1006/excr.1995.1218, 7628534.
21. Appel RD, Bairoch A, Sanchez JC, Vargas JR, Golaz O, Pasquali C, Hochstrasser DF. Federated two-dimensional electrophoresis database: a simple means of publishing two-dimensional electrophoresis data. Electrophoresis 1996, 17:540-546. 10.1002/elps.1150170324, 8740178.
22. Arikan S, Adas G, Barut G, Toklu AS, Kocakusak A, Uzun H, Kemik O, Daduk Y, Aydin S, Purisa S. An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing. Am J Surg 2005, 189:155-160. 10.1016/j.amjsurg.2004.11.002, 15720982.
23. Peplow PV. Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds. Thromb Haemost 2005, 94:4-16.
24. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. Faseb J 2005, 19:211-221. 10.1096/fj.04-1970com, 15677344.
25. Kinder BW, Collard HR, King TE. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 2006, 130:302-303. 10.1378/chest.130.1.302-a, 16840421.
26. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005, 128:1475-1482. 10.1378/chest.128.3.1475, 16162746.
27. Gerthoffer WT. Actin cytoskeletal dynamics in smooth muscle contraction. Can J Physiol Pharmacol 2005, 83:851-856. 10.1139/y05-088, 16333356.
28. Faure J, Vignais PV, Dagher MC. Phosphoinositide-dependent activation of Rho A involves partial opening of the RhoA/Rho-GDI complex. Eur J Biochem 1999, 262:879-889. 10.1046/j.1432-1327.1999.00458.x, 10411652.
29. Mehta D, Rahman A, Malik AB. Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J Biol Chem 2001, 276:22614-22620. 10.1074/jbc.M101927200, 11309397.
30. Rivero F, Illenberger D, Somesh BP, Dislich H, Adam N, Meyer AK. Defects in cytokinesis, actin reorganization and the contractile vacuole in cells deficient in RhoGDI. Embo J 2002, 21:4539-4549. 126189, 12198156, 10.1093/emboj/cdf449.
31. Sasaki T, Takai Y. The Rho small G protein family-Rho GDI system as a temporal and spatial determinant for cytoskeletal control. Biochem Biophys Res Commun 1998, 245:641-645. 10.1006/bbrc.1998.8253, 9588168.
32. Sun J, Barbieri JT. ExoS Rho GTPase-activating protein activity stimulates reorganization of the actin cytoskeleton through Rho GTPase guanine nucleotide disassociation inhibitor. J Biol Chem 2004, 279:42936-42944. 10.1074/jbc.M406493200, 15292224.
33. Takahashi K, Sasaki T, Mammoto A, Takaishi K, Kameyama T, Tsukita S, Takai Y. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem 1997, 272:23371-23375. 10.1074/jbc.272.37.23371, 9287351.
34. Granes F, Berndt C, Roy C, Mangeat P, Reina M, Vilaro S. Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic domain. FEBS Lett 2003, 547:212-216. 10.1016/S0014-5793(03)00712-9, 12860416.
35. Weiner OD, Neilsen PO, Prestwich GD, Kirschner MW, Cantley LC, Bourne HR. A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol 2002, 4:509-513. 10.1038/ncb811, 12080346.
36. Prehoda KE, Scott JA, Mullins RD, Lim WA. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science 2000, 290:801-806. 10.1126/science.290.5492.801, 11052943.
37. Ito H, Iwamoto I, Morishita R, Nozawa Y, Narumiya S, Asano T, Nagata K. Possible role of Rho/Rhotekin signaling in mammalian septin organization. Oncogene 2005, 24:7064-7072. 10.1038/sj.onc.1208862, 16007136.
38. Kodiha M, Chu A, Lazrak O, Stochaj U. Stress inhibits nucleocytoplasmic shuttling of heat shock protein hsc70. Am J Physiol Cell Physiol 2005, 289:C1034-1041. 10.1152/ajpcell.00590.2004, 15930140.
39. Desmouliere A, Rubbia-Brandt L, Grau G, Gabbiani G. Heparin induces alpha-smooth muscle actin expression in cultured fibroblasts and in granulation tissue myofibroblasts. Lab Invest 1992, 67:716-726.
40. Greenberg RS, Bernstein AM, Benezra M, Gelman IH, Taliana L, Masur SK. FAK-dependent regulation of myofibroblast differentiation. Faseb J 2006, 20:1006-1008. 10.1096/fj.05-4838fje, 16585062.
41. Ramos C, Montano M, Becerril C, Cisneros-Lira J, Barrera L, Ruiz V, Pardo A, Selman M. Acidic fibroblast growth factor decreases alpha-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. Am J Physiol Lung 2006, 291:L871-L879.
42. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003, 31:1108-1112. 10.1097/01.CCM.0000059441.70680.DC, 12682480.
43. Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 2003, 15:11-18. 10.1023/A:1026184100030, 14574071.
44. Lever R, Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001, 14:249-254. 10.1006/pupt.2001.0296, 11448151.
45. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002, 110:127-136. 151027, 12093896, 10.1172/JCI200214996.
46. Uthaiah RC, Praefcke GJ, Howard JC, Herrmann C. IIGP1, an interferon-gamma-inducible 47-kDa GTPase of the mouse, showing cooperative enzymatic activity and GTP-dependent multimerization. J Biol Chem 2003, 278:29336-29343. 10.1074/jbc.M211973200, 12732635.
47. Boehm U, Guethlein L, Klamp T, Ozbek K, Schaub A, Futterer A, Pfeffer K, Howard JC. Two families of GTPases dominate the complex cellular response to IFN-gamma. J Immunol 1998, 161:6715-6723.
48. Kaiser F, Kaufmann SH, Zerrahn J. IIGP, a member of the IFN inducible and microbial defense mediating 47 kDa GTPase family, interacts with the microtubule binding protein hook3. J Cell Sci 2004, 117:1747-1756. 10.1242/jcs.01039, 15075236.
49. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004, 1695:225-233. 10.1016/j.bbamcr.2004.10.004, 15571818.
50. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005, 15:27-33. 10.1016/j.tcb.2004.11.003, 15653075.
51. Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 2002, 100:2530-2536. 10.1182/blood.V100.7.2530, 12239166.
52. Daino H, Matsumura I, Takada K, Odajima J, Tanaka H, Ueda S, Shibayama H, Ikeda H, Hibi M, Machii T, Hirano T, Kanakura Y. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood 2000, 95:2577-2585.
53. Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L, Beal MF, Nishimura I, Wakamatsu K, Ito S, Takahashi R, Lu B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 2005, 102:13670-13675. 1224636, 16155123, 10.1073/pnas.0504610102.
54. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, Bray MR, Liu FF, Tsao MS, Mak TW. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005, 7:263-273. 10.1016/j.ccr.2005.02.010, 15766664.
55. Solway J, Seltzer J, Samaha FF, Kim S, Alger LE, Niu Q, Morrisey EE, Ip HS, Parmacek MS. Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J Biol Chem 1995, 270:13460-13469. 10.1074/jbc.270.22.13460, 7768949.
56. Nishida W, Kitami Y, Hiwada K. cDNA cloning and mRNA expression of calponin and SM22 in rat aorta smooth muscle cells. Gene 1993, 130:297-302. 10.1016/0378-1119(93)90435-6, 8359698.
57. Camoretti-Mercado B, Forsythe SM, LeBeau MM, Espinosa R, Vieira JE, Halayko AJ, Willadsen S, Kurtz B, Ober C, Evans GA, Thweatt R, Shapiro S, Niu Q, Qin Y, Padrid PA, Solway J. Expression and cytogenetic localization of the human SM22 gene (TAGLN). Genomics 1998, 49:452-457. 10.1006/geno.1998.5267, 9615232.
58. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001, 1:890-898. 10.1002/1615-9861(200107)1:7<890::AID-PROT890>3.0.CO;2-Z, 11503213.